Skip to main content
VivoSim Labs, INC. logo

VivoSim Labs, INC. — Investor Relations & Filings

Ticker · VIVS ISIN · US68620A2033 US Professional, scientific and technical activities
Open in API
Filings indexed 790 across all filing types
Latest filing 2021-02-01 Regulatory Filings
Country US United States of America
Listing US VIVS

About VivoSim Labs, INC.

https://organovo.com/

VivoSim Labs, Inc. is a biotechnology services company that develops and utilizes bioprinted, three-dimensional (3D) human tissues designed to emulate human biology and disease. The company provides testing services for drugs and drug candidates, primarily for the pharmaceutical and biotechnology sectors. VivoSim Labs specializes in offering liver and intestinal toxicology insights through its proprietary New Approach Methodologies (NAMs), including its NAMkind™ 3D models. These non-animal testing platforms are used to generate human-relevant safety and toxicology data early in the drug discovery and development process, aiming to provide insights before animal studies or clinical trials.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2021
Regulatory Filings
2021-02-01 English
424B5
Capital/Financing Update Classification · 100% confidence The document is a prospectus filed pursuant to Rule 424(b)(5) related to an offering of common stock up to $50 million. It details the terms of the sales agreement with agents, the offering process, risk factors, and other disclosures typical of a securities offering document. It is not a financial report, earnings release, or management discussion. It is a capital raising document describing the issuance of new shares. Therefore, it fits the category of Capital/Financing Update (CAP). The document length and content confirm it is the actual prospectus, not just an announcement of a report.
2021-01-29 English
Capital/Financing Update 2021
Capital/Financing Update Classification · 95% confidence The document is a letter from Organovo Holdings, Inc. to the SEC requesting acceleration of effectiveness for a Registration Statement on Form S-3. It references the Securities Act of 1933 and the Securities Exchange Act of 1934, and discusses the registration and offering of securities. There is no financial data, report content, or detailed financial analysis present. The document is a regulatory communication related to a capital raising registration statement, specifically a request for acceleration of effectiveness of a filing. This fits the category of Capital/Financing Update (CAP), which covers updates on company fundraising and financing activities.
2021-01-27 English
Regulatory Filings 2021
Regulatory Filings Classification · 90% confidence The provided document text appears to be encoded or encrypted and does not contain any readable content, keywords, regulatory headers, or fiscal period dates that would allow identification of a specific filing type. There is no indication of report titles, financial data, or announcements. Given the lack of discernible information, the document cannot be classified into any specific category and defaults to the fallback category for miscellaneous filings.
2021-01-22 English
S-3
Capital/Financing Update Classification · 100% confidence The document is a Form S-3 Registration Statement filed with the SEC, which is used for registering securities for public offering under the Securities Act of 1933. It includes detailed information about the securities to be offered, the registration fee, and the terms of the offering. This type of filing is related to capital raising activities and financing. It is not an annual report, earnings release, or any other type of financial or governance report. Therefore, it fits the category of Capital/Financing Update filings.
2021-01-19 English
8-K
Regulatory Filings Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated December 28, 2020, for Organovo Holdings, Inc. It reports the entry into a material definitive agreement (an Intercompany Agreement) between the company and related parties. The content focuses on the description of the agreement, parties involved, and approval by the Audit Committee. There are no financial statements or quarterly/yearly financial results presented. The document is a current report disclosing a material event rather than a financial report or earnings release. Therefore, it fits the category of a Regulatory Filing (RNS), which is the fallback for miscellaneous SEC filings like Form 8-K that do not fit other specific categories.
2020-12-31 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.